Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Peter R Hoffmann · UNIVERSITY OF HAWAII AT MANOA · 2023 · $388,500 — Selenium (Se) is an essential micronutrient important for many aspects of human health, including optimal immune responses. The biological effects of Se are exerted mainly through its incorporation into selenoproteins as the amino acid, selenocysteine (Sec). Twenty-five selenoproteins have been iden…
Milka Koupenova · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2023 · $418,750 — PROJECT SUMMARY Influenza infection increases the incidence of acute MI (AMI) within the first 7 days after detection and the therapeutic benefit of vaccination is comparable to current therapies for secondary prevention of AMI. Platelets are the blood component central to thrombosis and uncontroll…
ANEEL K. AGGARWAL · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $253,500 — Project Summary The Zika virus (ZIKV) is a member of the Flavivirus genus that includes other arthropod-borne human pathogens such as dengue virus and West Nile virus, among others. ZIKV’s link to microcephaly in newborn infants and the Guillan-Barré syndrome in adults has invigorated measures to de…
Zhilong Yang · TEXAS A&M AGRILIFE RESEARCH · 2023 · $378,750 — Project Summary Although smallpox had been eradicated, the chance the virus could arise from unknown stocks or de novo synthesis remains a credible biothreat. Moreover, other poxviruses cause significant morbidity and mortality in humans and economically important animals; and poxviruses are widely …
Joel H Collier · DUKE UNIVERSITY · 2023 · $437,499 — Even when vaccines are rapidly developed and shown to be efficacious and safe, vaccination campaigns continue to be hampered by public hesitancy and by challenges distributing vaccines equitably around the globe. Vaccine hesitancy, where individuals refuse or delay vaccination, has been a persistent…
Gundeep Singh Dhillon · STANFORD UNIVERSITY · 2023 · $422,438 — PROJECT SUMMARY / ABSTRACT Lung transplantation (LT) recipients suffer from life-threatening pulmonary infections that can trigger acute rejection and death. Although vaccination is the most effective way for preventing infections, vaccine efficacy is limited in immunocompromised solid organ transpl…
Kenneth Harold Dinnon · ROCKEFELLER UNIVERSITY · 2023 · $69,080 — PROJECT SUMMARY/ABSTRACT Alphaviruses are arthropod-transmitted viruses that cause acute febrile illness in humans, with some cases causing long-term skeletomuscular and neurological sequelae. Currently there are no FDA-approved vaccines or therapeutics for alphavirus infection, and continued globa…
Mariah L Arral · CARNEGIE-MELLON UNIVERSITY · 2023 · $43,814 — PROJECT ABSTRACT The goal of this research is to study the influence of age on the delivery processes required for lipid nanoparticle-mediated mRNA vaccination, with a long-term goal of improving vaccination outcomes in the elderly. In the next thirty years, our elderly population will double, exce…
Kristina M. Adams Waldorf · UNIVERSITY OF WASHINGTON · 2023 · $857,164 — Project Summary Pregnant women are highly vulnerable to influenza A virus (IAV) and are at increased risk for maternal death, preterm birth and stillbirth. Universal influenza vaccines (UFV) are thought to be possible if conserved regions of influenza virus are targeted and appropriate immune respon…
Cecilia Maria Leal · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · 2023 · $377,007 — PROJECT SUMMARY RNA therapeutics hold great promise for the treatment of a number of diseases significantly impacting human health, such as chronic infections, genetic disorders, certain cancers, and presently COVID-19. The leading RNA delivery vehicles approved by the FDA, as well as being consider…
Ross M Kedl · UNIVERSITY OF COLORADO DENVER · 2023 · $194,375 — Project summary. Clinically relevant cellular responses to either experimental or FDA approved vaccine adjuvant formulations have been difficult to generate and/or detect. We have long been investigating a combined adjuvant formulation (composed of a TLR agonist and an agonistic antiCD40 antibody) w…
ERIC T. KOOL · STANFORD UNIVERSITY · 2023 · $45,832 — Summary of parent project (R35 GM145357) Work in the last decade from many labs has underlined the critical importance of RNA-mediated cellular pathways, and clear connections of specific RNAs to human health. RNAs are increasingly viewed both as appealing therapeutic targets, and as therapeutic age…
Z Hong ZHOU · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $31,788 — PROJECT SUMMARY/ABSTRACT Double-stranded RNA (dsRNA) viruses comprise a large group of non-enveloped viruses characterized by their ability to transcribe their RNA within an intact capsid (i.e., endogenous RNA transcription), thus evading cellular antiviral responses to dsRNA. Among them, members of…
Paola Massari · TUFTS UNIVERSITY BOSTON · 2023 · $551,279 — Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection (STI) gonorrhea, a disease with high morbidity worldwide, estimated at 87 million cases annually, and severe reproductive tract complications in women. Current treatment approaches against gonorrhea are compromised by…
SAAD BHAMLA · GEORGIA INSTITUTE OF TECHNOLOGY · 2023 · $266,655 — Project Summary/Abstract Given modern history’s advancements in molecular biology, from the exponential decrease in the costs of genome sequencing, nucleotide synthesis, and genome editing (CRISPR), synthetic biology is poised to be the next major revolution in technological advancements. The White …
Xiaojing J Gao · STANFORD UNIVERSITY · 2023 · $193,094 — Abstract There is a critical need for RNA sensors in living mammalian cells. With the advent of single-cell RNA sequencing, the transcriptome of any cell type is readily obtainable if not already available. In contrast, we are still in urgent need for a universal method to act on such transcriptomi…
Harvey Michael Friedman · UNIVERSITY OF PENNSYLVANIA · 2023 · $812,498 — Abstract Genital herpes affects 650 million people globally. Vaccines are urgently needed to prevent infection and treat individuals already infected. During the current funding cycle, we developed a candidate vaccine for preventing genital herpes that uses nucleoside-modified mRNA encapsulated wit…
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2023 · $70,315 — PROJECT SUMMARY/ABSTRACT High-risk human papillomaviruses (HR HPVs) cause 5% of all cancers. There are preventive vaccines against HPV, but less than 2% of the world's target population has received them. This leaves millions of women and men at risk for HPV-associated cervical, anogenital, and hea…
Siyuan Ding · WASHINGTON UNIVERSITY · 2023 · $272,125 — Project Summary Small bowel intestinal epithelial cells (IECs) are the first line of defense against human enteric viruses, the most common and leading causes of diarrhea and death in infants and young children. How IECs communicate with intraepithelial lymphocytes (IELs) in the small intestine and…
Siyuan Ding · WASHINGTON UNIVERSITY · 2023 · $272,125 — Project Summary Diarrheal diseases account for 1 in 10 child deaths worldwide. Rotavirus (RV) and enterotoxigenic Escherichia coli (ETEC) are major etiological causes of acute gastroenteritis and severe diarrhea worldwide, together resulting in approximately 300,000 deaths each year, mostly in chil…